Concepedia

Amanda Mikels‐Vigdal

AM

12

Publications

1.2K

Citations

12

H-Index

2015

Active since

Affiliations

Gilead Sciences (United States)(Current)

University of Colorado Denver

University of Michigan

National Jewish Health

Indiana University School of Medicine

Amanda Mikels‐Vigdal is an author at Gilead Sciences (United States) specializing in medicine, cell biology, and immunology.

ORCID

Top concepts

Publications per year

2015–2023

12

Publications

12

Selective targeting of lysyl oxidase-like 2 (LOXL2) suppresses hepatic fibrosis progression and accelerates its reversal

Naoki Ikenaga, Zhenwei Peng, Kahini A. Vaid et al. · Gut · 2017 · 291 citations · Full text

Targeting LOXL2 for cardiac interstitial fibrosis and heart failure treatment

Jin Yang, Konstantinos Savvatis, Jong Seok Kang et al. · Nature Communications · 2016 · 261 citations · Full text

Selective Allosteric Inhibition of MMP9 Is Efficacious in Preclinical Models of Ulcerative Colitis and Colorectal Cancer

Derek Marshall, Susan K. Lyman, Scott McCauley et al. · PLoS ONE · 2015 · 190 citations · Full text

, , +12

Wnt signaling and Loxl2 promote aggressive osteosarcoma

Kazuhiko Matsuoka, Latifa Bakiri, Lena I. Wolff et al. · Cell Research · 2020 · 123 citations · Full text

MMP-9 inhibition promotes anti-tumor immunity through disruption of biochemical and physical barriers to T-cell trafficking to tumors

Vladi Juric, Chris O’Sullivan, Erin Stefanutti et al. · PLoS ONE · 2018 · 102 citations · Full text

Rows per page

1–5 of 12